Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

About PD-1 Inhibitors PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body’s ability to ...

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.

The expansion arm will assess the safety, optimal dosing, and early anti-tumor activity of Decoy20 in combination with tislelizumab. Initial participants will receive a week of Decoy20 monotherapy ...

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of ...

Indaptus began a new expansion phase of its Decoy20 trial, combining it with BeiGene’s tislelizumab to assess safety and anti-tumor activity The company expects its cash reserves to fund ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy as first-line treatment for unresectable or metastatic, PD-L1-positive ESCC.

PD-1 inhibitors like tislelizumab have shown promise in improving cancer outcomes, yet there remains a patient population that does not respond or sustain long-term benefits. Decoy20 is designed ...